Abstract Library

#4301 Case report on the effectiveness of combination therapy in highly aggressive resistant prolactinoma

Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,

Keywords: prolactinoma, IHC, Pit Net, chemotherapy,

#3505 DRD2 agonist cabergoline abolished the escape mechanism induced by mTOR inhibitor everolimus in pituitary neuroendocrine tumoral cells

Introduction: The mTOR inhibitor everolimus displays antimitotic effects on diverse neoplasms, including pituitary neuroendocrine ones (PitNETs); however, its effect is reduced by an escape mechanism that increases AKT phosphorylation (p-AKT) leading to survival pathway activation. Dopamine receptor type 2 (DRD2) reduces p-AKT in some non-functioning PitNETs (NF-PitNETs) and in lactotrophs MMQ cells, through a β-arrestin2-dependent mechanism.

Conference:

Presenting Author:

Authors: Mangili F, Esposito E, Treppiedi D, Catalano R, Marra G,

Keywords: pituitary neuroendocrine tumor, everolimus, mTOR/AKT pathway, β-arrestin 2, dopamine receptor type 2, cabergoline,

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#919 Effect of Combined Treatment with mTOR Inhibitors (mTORi) and Dopamine Agonists on Cell Proliferation in a Human Typical Lung Carcinoid Cell Line

Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Sarnataro M

Authors: Sarnataro M, Pivonello C, De Martino M, Sciammarella C, Cuomo G,

Keywords: mTOR, dopamine,

#532 Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line

Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pivonello R, Sarnataro M, Cariati F, Pivonello C, Colao A,

Keywords: neuroendocrine tumor, mTOR inhibitors, dopamine agonists, somatostatin analogues,